Stockreport

Eledon Pharmaceuticals: Tegoprubart Continues To Shine As Immunosuppressive Alternative [Seeking Alpha]

Eledon Pharmaceuticals, Inc.  (ELDN) 
PDF Company's tegoprubart demonstrated non-inferiority to tacrolimus and enabled insulin independence in 10/12 T1D islet transplant patients, with no toxic adverse events. [Read more]